Novel approaches to reduce temozolomide resistance in glioblastoma multiforme: a review of the literature
C. Jalili, I. Rashidi, M. Pazhouhi
World Cancer Research Journal · 2019
doi:10.32113/wcrj_201911_1431 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Temozolomide (TMZ), an oral alkylating agent, is currently used as a part of standard treatment for glioblastoma multiforme (GBM). GBM is considered one of the most lethal forms of human cancers, and despite recent improvement in cancer therapy, it remains an incurable disease, with a rare long-term survival of the patients due to the rapid emergence of cell clones resistant to treatment. Like other chemotherapeutic agents, resistance to TMZ is the major therapeutic obstacle to effective therapy; thereby, the development of new therapeutic strategies is required to overcome this problem. In the present review, an overview of the recent works on the reduction of TMZ resistance is presented.
Abstract licence: CC BY-NC-SA
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.